Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (7618)	4/22/1998 9:37:00 PM
From: Roger A. Babb	Read Replies (1) \| Respond to of 18691

Hank, boxing is very appropriate in these situations.

To: Hank who wrote (7618)	4/23/1998 10:56:00 AM
From: BDR	Read Replies (2) \| Respond to of 18691

Re ZONA: the May issue of the J. of Urology has a supplement that lists the abstracts of papers to be presented at the AUA national meeting in San Diego May 30-June 4. There is one paper on Vasomax. I doubt the publication of the supplement last week caused a rise in the stock. By the end of May the press may have saturated the market with Viagra stories and there may be place for some Vasomax coverage (hype) if ZONA manages it well. An abstract of the abstract: #919 Efficacy and Safety of Oral Phentolamine (Vasomax) for the Treatment of Minimal Erectile Dysfunction. Irwin Goldstein, Vasomax Study Group. Placebo-controlled, parallel group, double-blind randomized study: Placebo 16% 40mg 37% 80mg 45% Placebo-controlled crossover Placebo 21% 40mg 34% "...safe and effective oral medication for the treatment of mild erectile dysfunction."